Convacell / St. Petersburg Scientific Research Institute of Vaccines and Serums - LARVOL DELTA

Safety and Immunogenicity of the Convacell Recombinant N Protein COVID-19 Vaccine. (PubMed, Vaccines (Basel)) - "Convacell showed same level of immunological efficacy for single and double dose vaccination regimens, including for elderly patients. The clinical studies indicate that Convacell is safe and highly immunogenic."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell. (PubMed, Vaccines (Basel)) - "Vaccinated Syrian hamsters showed reduced lung histopathology, lower virus proliferation, lower lung weight relative to the body, and faster body weight recovery. Convacell thus is shown to be effective and may augment the existing armamentarium of vaccines against COVID-19."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older (clinicaltrials.gov) - P2/3 | N=16304 | Active, not recruiting | Sponsor: St. Petersburg Research Institute of Vaccines and Sera

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine. (clinicaltrials.gov) - P1/2 | N=155 | Completed | Sponsor: St. Petersburg Research Institute of Vaccines and Sera | Active, not recruiting ➔ Completed | Trial completion date: May 2022 ➔ Dec 2022

Trial completion • Trial completion date • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL2 • IL4

The Objectives of This Study Are Study the Immunogenicity, Safety and Tolerability of the Coronavirus Vaccine in Healthy Adult Volunteer Aged 18 to 60 Years. (clinicaltrials.gov) - P1/2; N=155; Active, not recruiting; Sponsor: St. Petersburg Research Institute of Vaccines and Sera

Clinical • New P1/2 trial • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL2 • IL4